Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CISTIC: Continuous vs Intermittent β-lactams in CF Exacerbations
NCT01667094Phase 4Unknown
- Sponsor
- Alfred Health
- Start
- Sep 2012
- Primary completion
- Jul 2017
- Modality
- Reversible Covalent Inhibitors, Implantable Devices, Transdermal Patches
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cefepime, ceftazidime, meropenem, piperacillin + tazobactam and ticarcillin plus clavulanic acid in cystic fibrosis (CF) and Pseudomonas aeruginosa infection, sponsored by Alfred Health. Status: unknown.
02
Drugs
cefepimeceftazidimemeropenempiperacillin + tazobactamticarcillin plus clavulanic acid
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT01667094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01667094.